Medical Oncology
Prof. Dr. (Associate) Sema Türker
1. Cancer Diagnosis and Staging
• Interpreting imaging studies (e.g., PET/CT, MRI, and X-rays)
• Biopsy analysis and pathology reports
• Tumor markers and genetic profiling (e.g., OncoDeep, FoundationOne)
• Assessing disease stage and spread (TNM staging)
2. Systemic Cancer Treatments
• Chemotherapy: Traditional cytotoxic drug regimens
• Immunotherapy: Immune checkpoint inhibitors, CAR T-cell therapy
• Targeted Therapy: EGFR inhibitors, HER2 inhibitors, BRAF inhibitors, etc.
• Hormonal Therapy: For hormone-sensitive cancers like breast and prostate
• Biologic Therapy: Monoclonal antibodies and biosimilars
• Experimental/Novel Therapies: Participation in clinical trials
3. Cancer-Specific Expertise
• Breast cancer
• Lung cancer
• Colorectal cancer
• Pancreatic cancer
• Prostate cancer
• Gynecologic cancers (e.g., ovarian, endometrial)
• Hematologic malignancies (e.g., lymphomas, leukemias)
• Pediatric oncology
• Rare cancers (e.g., sarcomas, neuroendocrine tumors)
4. Precision Medicine
• Genomic and molecular profiling of tumors
• Personalized treatment strategies
• Biomarker testing (e.g., PD-L1, MSI, BRCA mutations)
5. Palliative Care and Symptom Management
• Pain management
• Managing side effects of treatments (e.g., nausea, fatigue, neuropathy)
• Improving quality of life
• End-of-life care and decision-making
6. Multidisciplinary Coordination
• Collaborating with surgeons, radiation oncologists, pathologists, and radiologists
• Case discussions in tumor boards
• Coordinating complex treatment plans
7. Cancer Screening and Prevention
• Risk assessment and genetic counseling (e.g., BRCA, Lynch syndrome)
• Education on lifestyle modifications and cancer prevention
• Screening protocols for high-risk populations
8. Survivorship Care
• Monitoring for recurrence
• Long-term follow-up and late effects of treatment
• Psychosocial support and counseling
9. Research and Clinical Trials
• Conducting or participating in research for new cancer therapies
• Involvement in Phase I, II, and III clinical trials
Education:
Education and Specialization
1998 - 2004 – Ankara University Faculty of Medicine
2004 - 2010 – Akdeniz University Faculty of Medicine, Specialization in Internal Medicine
2016 - 2019 – Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Specialization in Medical Oncology
Academic Appointments:
2010 - 2011 – Polatlı Duatepe State Hospital, Internal Medicine Specialist
2011 - 2016 – Marmaris State Hospital, Internal Medicine Specialist
2014 - 2015 – Gölcük Necati Çelik State Hospital, Internal Medicine Specialist
2016 – Ankara Training and Research Hospital, Internal Medicine Specialist
2016 - 2019 – Ankara Dışkapı Yıldırım Beyazıt Training and Research Hospital, Subspecialty Assistant in Medical Oncology
2019 - 2021 – Zonguldak Bülent Ecevit University, Medical Oncology Specialist
2019 - 2021 – Zonguldak Atatürk State Hospital, Medical Oncology Specialist
Courses and Certificates
TTOD Medical Oncology Proficiency Certificate
TİHUD Internal Medicine Proficiency Certificate
MedicReS Good Reviewer Certificate
MedicReS Good Medical Researcher Certificate
Professional Memberships
Turkish Society of Medical Oncology (TTOD)
American Society of Clinical Oncology (ASCO)
Turkish Society of Internal Medicine Specialists (TİHUD)
Turkish Medical Association
• Türker Sema, Çılbır E, Yilmaz KB, Yetişgin E, İmamoğlu G, İnan K, Şahinli H, Altınbaş M. “Tumor-to-tumor metastasis: Breast cancer metastasis to lung cancer” Breast J. 2020 Mar; 26(3):534-535. doi: 10.1111/tbj.13558. Epub 2019 Sep 29. PMID: 31565825.
• Türker Sema, Cilbir E, Karacin C, Altinbas M. “Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment” J Cancer Res Ther. 2020 Apr-Jun;16(3):690-692. doi: 10.4103/jcrt.JCRT_343_17. PMID: 32719294.
• Türker Sema, Cilbir E, Guven DC, Karacin C, Yalcin S. “The relation between inflammation-based parameters and survival in metastatic pancreatic cancer” J Cancer Res Ther. 2021 Apr-Jun;17(2):510-515. doi: 10.4103/jcrt.JCRT_773_19. PMID: 34121700.
• Türker, Sema, Cilbir, E., Güven, D. C., Sahinli, H., Karaçin, C., & Yalçin, S. (2021). “The Prognostic Role of AB0 Blood Groups In Pancreas Cancer” Eastern Journal of Medicine, 26(2), 224-227.
• Türker, Sema, Karaçin, C., İmamoğlu, G. İ., Eren, T., Esen, R., Çılbır, E., ... & Yazılıtaş, D. (2018). “Kolon kanserinde lokalizasyon ile nötrofil lenfosit oranı arasındaki ilişki” Ortadoğu Tıp Dergisi, 10(1), 64-67.
• Turker, Sema, Sahinli, H., Perkin, P., Yazilitas, D., Koklu, N. O., Imamoglu, G. I., ... & Altinbas, M. (2018).“Squamos cell lung cancer" case applying with dyspepsia complaints” Journal of Oncological Sciences, 4(3), 147-148.
• Karacin C, Türker Sema, Eren T, Imamoglu GI, Yılmaz K, Coskun Y, Gunes SO, Sökmen F, Yazilitas D, Şimşek Z, Altınbaş M. Predictors of Neoplasia in Colonic Wall Thickening Detected via Computerized Tomography. Cureus. 2020 Sep 20;12(9):e10553. doi: 10.7759/cureus.10553. PMID: 32968607; PMCID: PMC7505674.
• Sahinli H, Türker Sema, “The hematologic inflammatory index is a new prognostic marker in patients resected for gastric cancer” J Cancer Res Ther. 2020 Dec;16(Supplement):S144-S149. doi: 10.4103/jcrt.JCRT_560_19. PMID: 33380669.
• Erin N, Türker Sema, Elpek Ö, Yildirim B. “ADAM proteases involved in inflammation are differentially altered in patients with gastritis or ulcer”Exp Ther Med. 2018 Feb;15(2):1999-2005. doi: 10.3892/etm.2017.5619. Epub 2017 Dec 12. PMID: 29434796; PMCID: PMC5776559.
• Erin N, Türker Sema, Elpek O, Yıldırım B. “Differential changes in Substance P, VIP as well as neprilysin levels in patients with gastritis or ulcer”Peptides. 2012 Jun;35(2):218-24. doi: 10.1016/j.peptides.2012.03.018. Epub 2012 Mar 29. PMID: 22484287.
• Coban E, Küçüktağ Sema, Basyigit S.“Platelet activation in subjects with impaired glucose tolerance. Platelets” 2007 Dec;18(8):591-4. doi: 10.1080/09537100701609019. PMID: 18041650.
• Yazisiz V, Arslan G, Ozbudak IH, Türker Sema, Erbasan F, Avci AB, Ozbudak O, Terzioglu E. “Lung involvement in patients with primary Sjögren's syndrome: what are the predictors?”Rheumatol Int. 2010 Aug;30(10):1317-24. doi: 10.1007/s00296-009-1152-8. Epub 2009 Oct 21. PMID: 19844720.